Q1 Results: Biocon Sees Two Segments Driving Its Growth In 2019-20
Biocon is seeing a good visibility in terms of order book and projects on hand, says Chairperson Kiran Mazumdar Shaw.
Biocon Ltd. expects its biologics and small molecules businesses to continue its growth momentum in 2019-20, Chairperson and Managing Director Kiran Mazumdar Shaw said on Friday.
The company is seeing a good visibility in terms of order book and projects on hand, she told BloombergQuint in an interview. “Overall, we’re going to have a very strong FY20.”
The biologics segment’s revenue jumped 96 percent over last year to Rs 490 crore in the June quarter, the Bengaluru-based biotechnology firm said in an exchange filing. Its small molecule division’s revenue grew 20 percent over the same period. Revenue of the company’s branded formulations arm fell 9 percent year-on-year to Rs 133 crore.
Biocon Q1 Results 2019-20: Key Highlights (YoY)
- Revenue rose 30.4 percent to Rs 1,465.9 crore.
- Net profit increased 72.3 percent to Rs 206.3 crore.
- Ebitda rose 84 percent to Rs 437.5 crore.
- Margin stood at 29.8 percent versus 21.2 percent.
Watch the full interaction here: